This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
The resolution, however, does not authorize the commercial sale of entheogenic plants and fungi, nor cultivation for large-scale distribution.
The leader of the Conservative Party in the United Kingdom tells a Member of Parliament “we will consider the Advisory Council on the Misuse of Drugs’ recent advice on reducing barriers to research with controlled drugs.”
A Johns Hopkins Medicine professor says “it was only a matter of time,” while lead researcher calls the historic grant “monumental” for the psychedelics movement.
“Let’s spend the time researching, looking into how these plant medicines were made to help us,” the two-time Grammy winner says during end-of-life psychedelic conference.
There is currently no known cure for dementia, but Return Health CEO Dr. James Kuo says psychedelics offer “unprecedented” potential.
Researchers say there are several ways classic psychedelics could, directly and indirectly, lead to improved cardiometabolic health.
“As traditional treatment has proven inadequate at both the individual and public health level, the Commonwealth has a responsibility to research alternative options,” the bill’s sponsors write in a memo.
CEO James Lanthier compares psychedelic medicines to aspirin, and explains why the company’s lead candidate may be better than psilocybin.
Planting, cultivating, purchasing, transporting, distributing, possessing these plants and fungi will be the lowest law enforcement priority for the city.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.